Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference
Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Piper Sandler 35th Annual Healthcare Conference, held from November 28th to November 30th, 2023, at Lotte New York Palace in New York City. Paul Truex, Thryv’s Chairman of the Board & Chief Executive Officer, will present on November 29th from 3:50 to 4:10 PM in Harlem Track, Kennedy 2, 4th floor.
Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions
Thryv Therapeutics Inc. is pleased to announce an oral presentation of the effects of SGK-1 inhibition with its potent and selective inhibitor THRV-1268 on atrial fibrillation in an obese-mouse model. This abstract will be presented during the Shocking Results: Basic Science Insights into Arrhythmias session at the American Heart Association Annual Scientific Sessions in Philadelphia, PA.
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study in Long QT Syndrome.
Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT. LQT-1213 is a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase 1 (SGK-1), which is implicated in QTc prolongation.
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting
Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) for THRV-1257. THRV-1257 is being investigated for the treatment of advanced Anaplastic Thyroid Cancer (ATC), including those patients with the common BRAF mutation V600E. The first in human study will determine the optimal dosing of THRV-1257 in patients with solid tumors, followed by treatment in combination with approved cancer therapies.
Lizzy’s lifelong journey with Long QT Syndrome
Lizzy's journey with Long QT Syndrome began at birth when a nurse noticed her low heartbeat, leading to comprehensive monitoring and the identification of her arrhythmia. She was immediately transported to the Children's Hospital of Philadelphia, where she was diagnosed with Long QT Syndrome Type 3.
Inside Thryv - A Conversation with Marc Vidal, Senior Director, Product & Process Development
Join us as we introduce Marc Vidal, our Senior Director of Product & Process Development at Thryv. Discover Marc’s journey in the sciences, how it lead him to be the first employee to join the Thryv team, and learn how he consistently works to #berelentless in pursuit of innovation!
Ashley, Peyton & Avery’s LQTS Story
The family hopes that by sharing their story, people will evaluate how prepared they are for a cardiac event. Whether it's through CPR training or having AEDs in schools, they want to change the narrative of "it won't happen to me".
Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec
While we await results from our initial proof of efficacy study this summer in Long QT Syndrome, we are able to accelerate a number of pipeline initiatives thanks to this new investment from IQ.
Inside Thryv - A Conversation with Shannon Hewgill, Research Associate
Curious about the behind-the-scenes of Thryv's oncology program development? Meet Shannon Hewgill, our Research Associate who's work in the lab is helping develop the oncology program from the ground up.
Abrielle was two when diagnosed with LQTS Type 3
Two weeks after doctors told her parents she was the “picture of health”, Abrielle suffered a sudden cardiac arrest. Fortunately, her father was able to perform CPR until emergency personnel arrived.
Rob’s not stopping for LQTS Type 2
Rob’s message to the Long QT community is to not fear their diagnosis. He lives his life by the same philosophy he applies in racing: Control what you can control.
Inside Thryv - A Conversation with Debra Odink, President & CDO
In our new series, ‘Inside Thryv - Conversations with Employees,’ we sit down with our team members to learn about their roles and how they help drive our mission forward. First up is Thryv’s President & Chief Development Officer, Debra Odink!
Lizzie Presents to the Brigham & Women’s Hospital
Lizzie hopes sharing her experiences raising a child with an ICD and diagnosed Long QT Type 15, she will reach people it can help.
Complete the 10-minute SADS Research Survey & Help Change Lives
The SADS Foundation is working with companies almost ready to recruit participants for first-of-their-kind clinical trials. But first, they need to learn more about the SADS community through this ten-minute survey so they can help connect you to research studies.
SADS Live interview with Thryv Therapeutics
Three of our team were invited to join Dr. Michael Ackerman as part of the SADS Live program. We invite you to watch this interview to learn more about our passionate team and progress, what the next steps are as we move into clinical studies, and what we are doing to challenge the current LQTS treatments.
What a great year we had at Thryv!
2022 was a big year for Thryv Therapeutics, and 2023 is shaping up to be even bigger. Debra Odink, President & Chief Development Officer, shares her wrap-up of the year.
Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., Appointed to Thryv’s Board of Directors
Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers.
34th Piper Sandler Annual Healthcare Conference and RBC Capital Markets Healthcare Private Company Virtual Conference
Two fireside chats by Mr. Paul F. Truex CEO on Thryv’s progress with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.
Scientific Data for Thryv’s Novel SGK1 inhibitors Presented at American Heart Association and San Antonio Breast Cancer Symposium
Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago
Dr. Debra Odink appointed to President and Dr. Shi Yin Foo joins Thryv’s Board of Directors
We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.